Immuneering Corporation (IMRX) Actualités

Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]

Form 8-K - Current report

Immuneering Provides Positive Update on Phase 2a Arm Studying IMM-1-104 in Combination with Modified FOLFIRINOX for First-Line Pancreatic Cancer

- Two new partial responses (PRs) reported in Phase 2a arm studying IMM-1-104 in combination with modified...

Form 8-K - Current report

Immuneering Announces Positive Data Update from Three Pancreatic Cancer Arms of Ongoing Phase 2a Trial of IMM-1-104; Plans to Expand Trial with Additional Arms

- Updated data for IMM-1-104 in combination with modified gemcitabine/nab-paclitaxel (mGnP) in first-line...

Form 4 - Statement of changes in beneficial ownership of securities

Immuneering Launches Pancreatic Cancer Advisory Board

- Establishment reflects the clinical progress of IMM-1-104 and its promise in pancreatic cancer - - Follows...

Immuneering to Present Data from Three Arms of its Ongoing Phase 2a Trial of IMM-1-104 in Early January 2025

- The company will provide additional data from IMM-1-104 in combination with modified gemcitabine/nab-paclitaxe...

Immuneering Granted FDA Fast Track Designation for IMM-1-104 in Advanced Melanoma

- IMM-1-104 has the potential to benefit melanoma patients who have progressed on or are intolerant to immune...

Immuneering to Present at the Piper Sandler 36ᵗʰ Annual Healthcare Conference

CAMBRIDGE, Mass., Nov. 27, 2024 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage...

Immuneering Reports Third Quarter 2024 Financial Results and Provides Business Updates

- Announced Positive Initial Data, Including Complete and Partial Responses, with IMM-1-104 in Combination with...

Form 8-K - Current report

Immuneering Granted Orphan Drug Designation for IMM-1-104 by FDA in the Treatment of Pancreatic Cancer

- Immuneering recently announced positive initial Phase 2a data, including complete and partial responses, with...

Form 8-K/A - Current report: [Amend]

Form 4 - Statement of changes in beneficial ownership of securities